New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022

Int J Mol Sci. 2022 May 29;23(11):6084. doi: 10.3390/ijms23116084.

Abstract

Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with anti-melanoma activity. This review focuses on the most recent synthesized anti-melanoma agents from 2020-2022. For selected agents, apart from the analysis of biological activity, the structure-activity relationship (SAR) is also discussed. To the best of our knowledge, the following literature review delivers the latest achievements in the field of new anti-melanoma agents.

Keywords: BRAF kinase; MAPK pathway; PI3K–AKT pathway; anticancer activity; cancer; heterocyclic derivatives; ion channels; melanoma; targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Melanoma* / pathology
  • Melanoma, Cutaneous Malignant
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf

Grants and funding

This research received no external funding.